(-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts

Breast Cancer Research and Treatment

Volumn 76, Issue 3, 2002, Pages 195-201

  Vergote, David ^a   Cren Olivé, Cécile ^a   Chopin, Valérie ^a   Toillon, Robert Alain ^a   Rolando, Christian ^a   Hondermarck, Hubert ^a   Bourhis, Xuefen Le ^a  

^a UNIV LILLE   (France)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Fas signaling; Flavan 3 ols; Tea polyphenols

Indexed keywords

CASPASE 10; CASPASE 8; CASPASE INHIBITOR; EPICATECHIN; EPIGALLOCATECHIN; FAS ANTIBODY; FAS ANTIGEN; FLAVAN DERIVATIVE; POLYPHENOL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; BAX PROTEIN, HUMAN; CASPASE; CATECHIN; CYCLIN D1; DRUG DERIVATIVE; FATTY ACID SYNTHASE; GALLOCATECHIN; ONCOPROTEIN;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN MCF 7; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TEA; WILD TYPE; BREAST; BREAST TUMOR; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; GENETICS; METABOLISM;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST; BREAST NEOPLASMS; CASPASES; CATECHIN; CELL CYCLE; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0036890344     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020833410523     Document Type: Article

References (34)

1. Stoner GD, Mukhtar H: Polyphenols as cancer chemoprevenrive agents. J Cell Biochem 22(suppl): 169-180, 1995
2. Katiyar SK, Mukhtar H: Tea in chemoprevention of cancer: Epidemiologic and experimental studies. Int J Oncol 8: 221-238, 1996 (Review)
3. Bushman JL: Green tea and cancer in humans: A review of literature. Nutr Cancer 31: 151-159, 1998
4. Gupta S, Ahmad N, Mukhtar H: Prostate cancer chemoprevention by green tea. Semin Urol Oncol 17: 70-76, 1999
5. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y: Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 89: 254-261, 1998
6. Zhao B, Guo Q, Xin W: Free radical scavenging by green tea polyphenols. Method Enzymol 338: 204-217, 2001
7. Serafini M, Ghiselli A, Ferro-Luzzi A: In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr 50: 28-32, 1996
8. Wang ZY, Cheng SJ, Zhou ZC, Athar M, Khan WA, Bickers DR, Mukhtar H: Antimutagenic activity of green tea polyphenols. Murat Res 223: 273-285, 1989
9. Kuroda Y, Hara Y: Antimutagenic and anticarcinogenic activity of tea polyphenols. Murat Res 436: 69-97, 1999
10. Rice-Evans CA, Miller NJ, Paganga G: Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radical Biol Med 20: 933-956, 1996
11. Chen ZP, Schell JB, Ho CT, Chen KY: Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett 129: 173-179, 1998
12. Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG: Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19: 419-424, 1998
13. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 89: 1881-1886, 1997
14. Yang GY, Liao L, Kim K, Yurkow EJ, Yang CS: Inhibition of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998
15. Ahmad N, Gupta S, Mukhtar H: Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 376: 338-346, 2000
16. Valcic S, Timmermann BN, Alberts DS, Wächter GA, Krutzsch M, Wymer J, Guillèn JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human rumor cell lines. Anticancer Drugs 7: 461-468, 1996
17. Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM, Calvo F: Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer 71: 42-48, 1997
18. Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP, Hondermarck H: Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 276: 17,864-17,870, 2001
19. Toillon RA, Adriaenssens E, Wouters D, Lottin S, Boilly B, Hondermarck H, Le Bourhis X: Normal breast epithelial cells induce apoptosis of MCF-7 breast cancer cells through a p53-mediated pathway. Mol Cell Biol Res Commun 3: 338-344, 2000
20. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K: Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93: 3053-3063, 1999
21. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y: Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 20: 1852-1859, 2001
22. Juo P, Kuo CJ, Yuan J, Blenis J: Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 8: 1001-1008, 1998
23. Okabe S, Suganuma M, Hayashi M, Sueoka E, Komori A, Fujiki H: Mechanisms of growth inhibition of human lung cancer cell line, PC-9, by tea polyphenols. Jpn J Cancer Res 88: 639-643, 1997
24. Fujiki H, Suganuma M, Okabe S, Sueoka N, Komori A, Sueoka E, Kozu T, Tada Y, Suga K, Imai K, Nakachi K: Cancer inhibition by green tea. Murat Res 402: 307-310, 1998
25. Johnston SR: Acquired tamoxifen resistance in human breast cancer - Potential mechanisms and clinical implications. Anticancer Drugs 8: 911-930, 1997
26. England GM, Jordan VC: Pure antiestrogens as a new therapy for breast cancer. Oncol Res 9: 397-402, 1997
27. Weller M: Predicting response to cancer chemotherapy: The role of p53. Cell Tissue Res 292: 435-445, 1998
28. Pirollo KF, Bouker KB, Chang EH: Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11: 419-432, 2000
29. Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: A critical analysis. Adv Cancer Res 66: 71-141, 1995
30. Hartmann A, Blaszyk H, Kovach JS, Sommer SS: The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13: 27-33, 1997
31. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322-1326, 1998
32. Kroemer G, Reed JC: Mitochondrial control of cell death. Nat Med 6: 513-519, 2000
33. Nagata S, Golstein P: The Fas death factor. Science 267: 1449-1456, 1995
34. Hayakawa S, Saeki K, Sazuka M, Suzuki Y, Shaoji Y, Ohta T, Kaji K, Yuo A, Isemura M: Apoptosis induction by epigallocatechin gallate involves its binding to Fas. Biochem Biophys Res Comm 285: 1102-1106, 2001